Perrigo wins US FDA approval of generic seborrheic dermatitis drug
This article was originally published in Scrip
Executive Summary
Perrigo won US FDA approval for its generic drug ketoconazole foam 2% as a topical treatment of seborrheic dermatitis in immunocompetent patients 12 years or older.